Q4 2023 13F Holders as of 12/31/2023
-
Type / Class
-
Equity / Common Stock, par value $0.01 per share
-
Shares outstanding
-
34.7M
-
Number of holders
-
70
-
Total 13F shares, excl. options
-
21.9M
-
Shares change
-
-620K
-
Total reported value, excl. options
-
$182M
-
Value change
-
-$5.23M
-
Put/Call ratio
-
0.17
-
Number of buys
-
33
-
Number of sells
-
-43
-
Price
-
$8.31
Significant Holders of IGM Biosciences, Inc. - Common Stock, par value $0.01 per share (IGMS) as of Q4 2023
95 filings reported holding IGMS - IGM Biosciences, Inc. - Common Stock, par value $0.01 per share as of Q4 2023.
IGM Biosciences, Inc. - Common Stock, par value $0.01 per share (IGMS) has 70 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 21.9M shares
of 34.7M outstanding shares and own 63% of the company stock.
Largest 10 shareholders include BAKER BROS. ADVISORS LP (3.69M shares), PRICE T ROWE ASSOCIATES INC /MD/ (3.26M shares), Artal Group S.A. (3.1M shares), Redmile Group, LLC (2.97M shares), FMR LLC (1.7M shares), GOLDMAN SACHS GROUP INC (1.04M shares), RA CAPITAL MANAGEMENT, L.P. (938K shares), VANGUARD GROUP INC (897K shares), BlackRock Inc. (762K shares), and ADAGE CAPITAL PARTNERS GP, L.L.C. (400K shares).
This table shows the top 70 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.